-
公开(公告)号：US20180094066A1
公开(公告)日：2018-04-05
申请号：US15601884
申请日：2017-05-22
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Nicholas J. PAPADOPOULOS , Gavin Thurston , Jessica R. Kirshner , Marcus P. Kelly , Thomas Nittoli , Frank J. Delfino
IPC: C07K16/28 , A61K31/537 , A61K39/00
CPC classification number: C07K16/2866 , A61K31/537 , A61K47/6803 , A61K47/6849 , A61K2039/505 , C07K16/2869 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94
Abstract: The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders. The present invention also includes antibody drug conjugates comprising an antibody or antigen-binding fragment thereof that specifically binds a class I cytokine receptor, wherein the antibody or antigen-binding fragment thereof is conjugated to a cytotoxic agent.
-
公开(公告)号：US20180051066A1
公开(公告)日：2018-02-22
申请号：US15624845
申请日：2017-06-16
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Nicholas J. PAPADOPOULOS , Samuel DAVIS , George D. YANCOPOULOS
CPC classification number: C07K14/71 , A61K38/00 , C07H21/04 , C07K16/22 , C07K19/00 , C07K2319/00 , C07K2319/30 , C12N15/09 , C12N15/10
Abstract: The present invention provides VEGF antagonists with improved pharmacokinetic properties. According to certain embodiments, a fusion polypeptide capable of antagonizing VEGF activity is provided comprising a modified extracellular ligand binding domain of a VEGF receptor fused to a multimerizing component.
-
公开(公告)号：US20130344093A1
公开(公告)日：2013-12-26
申请号：US13925923
申请日：2013-06-25
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： Christopher DALY , Gavin THURSTON , Nicholas J. PAPADOPOULOS
IPC: A61K39/395
CPC classification number: A61K39/39558 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/2863 , C07K2317/21 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/92 , C07K2317/94
Abstract: The present invention provides antibodies that bind to EGFR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human EGFR with high affinity. In certain embodiments, the antibodies of the present invention are capable of inhibiting the growth of tumor cells expressing high levels of EGFR and/or inducing antibody-dependent cell-mediated cytotoxicity (ADCC) of such cells. The antibodies of the invention are useful for the treatment of various cancers as well as other EGFR-related disorders.
-
公开(公告)号：US20130243775A1
公开(公告)日：2013-09-19
申请号：US13798205
申请日：2013-03-13
Applicant: REGENERON PHARMACEUTICALS, INC.
IPC: C07K16/28
Abstract: The present invention provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone. In other embodiments of the invention, the target molecule is a tumor associated antigen, and the simultaneous binding of the tumor associated antigen and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention causes or facilitates the targeted killing of tumor cells.
Abstract translation: 本发明提供多特异性抗原结合分子及其用途。 多特异性抗原结合分子包含特异性结合靶分子的第一抗原结合结构域和特异性结合内在效应蛋白的第二抗原结合结构域。 在一些实施方案中，本发明的多特异性抗原结合分子可以是能够结合靶分子和内化效应蛋白的双特异性抗体。 在本发明的某些实施方案中，通过本发明的多特异性抗原结合分子同时结合靶分子和内化效应蛋白导致目标分子的活性比所述靶分子的结合更大程度地减弱 靶分子单独。 在本发明的其它实施方案中，靶分子是肿瘤相关抗原，并且通过本发明的多特异性抗原结合分子同时结合肿瘤相关抗原和内在效应蛋白导致或促进靶向杀伤肿瘤细胞 。
-
公开(公告)号：US20210163611A1
公开(公告)日：2021-06-03
申请号：US17064393
申请日：2020-10-06
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： Joel H. MARTIN , Tammy T. HUANG , Jeanette L. FAIRHURST , Nicholas J. PAPADOPOULOS , George D. YANCOPOULOS
IPC: C07K16/28 , A61K39/395 , A61K45/06 , A61K39/00
Abstract: The present invention provides nucleic acid molecules that encode antibodies or antigen-binding fragments thereof, which specifically bind human interleukin-4 receptor (lL-4R). Also provided are expression vectors comprising nucleic acid molecule that encode anti-lL-4R antibodies, host cells comprising the expression vectors, and methods of producing anti-lL-4R antibodies or antigen-binding fragments thereof comprising growing the host cells under conditions permitting production of the antibody or fragment, and recovering the antibody or fragment so produced.
-
Patent Agency Ranking
公开(公告)号：US20180179288A1
公开(公告)日：2018-06-28
申请号：US15874635
申请日：2018-01-18
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Joel H. MARTIN , Tammy T. HUANG , Jeanette L. FAIRHURST , Nicholas J. PAPADOPOULOS
IPC: C07K16/28 , A61K45/06 , A61K39/395 , A61K39/00
CPC classification number: C07K16/2866 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/76 , C07K2317/92
Abstract: The present invention provides nucleic acid molecules that encode antibodies or antigen-binding fragments thereof, which specifically bind human interleukin-4 receptor (IL-4R). Also provided are expression vectors comprising nucleic acid molecule that encode anti-IL-4R antibodies, host cells comprising the expression vectors, and methods of producing anti-IL-4R antibodies or antigen-binding fragments thereof comprising growing the host cells under conditions permitting production of the antibody or fragment, and recovering the antibody or fragment so produced.
-
公开(公告)号：US20160251442A1
公开(公告)日：2016-09-01
申请号：US15051580
申请日：2016-02-23
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： Nicholas J. PAPADOPOULOS , Gavin THURSTON , Jessica R. KIRSHNER , Marcus P. KELLY , Thomas NITTOLI , Frank J. DELFINO
CPC classification number: C07K16/2866 , A61K31/537 , A61K47/6803 , A61K47/6849 , A61K2039/505 , C07K16/2869 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94
Abstract: The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders. The present invention also includes antibody drug conjugates comprising an antibody or antigen-binding fragment thereof that specifically binds a class I cytokine receptor, wherein the antibody or antigen-binding fragment thereof is conjugated to a cytotoxic agent.
-
公开(公告)号：US20170260293A1
公开(公告)日：2017-09-14
申请号：US15601614
申请日：2017-05-22
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： George D. YANCOPOULOS , Nicholas J. PAPADOPOULOS , Neil STAHL , Samuel DAVIS , Andrew J. MURPHY , Lynn MACDONALD
CPC classification number: C07K16/468 , C07K16/2803 , C07K16/2809 , C07K16/2887 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/52 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/569 , C07K2317/622 , C07K2317/64
Abstract: Multivalent antigen-binding proteins comprising two or three or four or more immunoglobulin heavy chain variable domain binding domains are provided, as are methods for making them, nucleic acid constructs, and cell lines for making them. Proteins comprising two or three or four or more different heavy chain variable domains that lack an immunoglobulin variable domain are provided. Proteins comprising two or three or four or more different heavy chain variable domains that associate with the same immunoglobulin light chain variable domain are also provided.
-
公开(公告)号：US20160229916A1
公开(公告)日：2016-08-11
申请号：US15136152
申请日：2016-04-22
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： Sean STEVENS , Tammy T. HUANG , Joel H. MARTIN , Jeanette L. FAIRHURST , Ashique RAFIQUE , Eric SMITH , Kevin J. POBURSKY , Nicholas J. PAPADOPOULOS , James P. FANDL , Gang CHEN , Margaret KAROW
IPC: C07K16/28
CPC classification number: C07K16/2866 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.
-
公开(公告)号：US20150056222A1
公开(公告)日：2015-02-26
申请号：US14530265
申请日：2014-10-31
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Nicholas J. PAPADOPOULOS , Gavin THURSTON , Jessica R. KIRSHNER , Marcus P. KELLY , Thomas NITTOLI , Frank J. DELFINO , William C. OLSON , Yashu LIU
CPC classification number: A61K47/48561 , A61K39/3955 , A61K47/48384 , A61K47/6803 , A61K47/6849 , C07K16/2869 , C07K16/30 , C07K2317/21 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92
Abstract: The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. According to certain embodiments, the invention includes antibodies that bind to the first fibronectin-like type III domain of the extracellular domain of PRLR. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders. The present invention also includes antibody drug conjugates comprising an antibody or antigen-binding fragment thereof that specifically binds a class I cytokine receptor, wherein the antibody or antigen-binding fragment thereof is conjugated to a cytotoxic agent.
Abstract translation: 本发明提供了结合催乳素受体（PRLR）的抗体及其使用方法。 根据某些实施方案，本发明的抗体以高亲和力结合人PRLR。 在某些实施方案中，本发明包括结合PRLR并阻断催乳素介导的细胞信号传导的抗体。 在其它实施方案中，本发明包括结合PRLR但不阻断催乳素介导的细胞信号传导的抗体。 根据某些实施方案，本发明包括结合PRLR细胞外结构域的第一纤连蛋白样III型结构域的抗体。 本发明的抗体可以是完全人抗体。 本发明包括与细胞毒性剂，放射性核素或对细胞生长或增殖有害的其它部分缀合的抗PRLR抗体。 本发明的抗体可用于治疗各种癌症以及其它PRLR相关疾病。 本发明还包括抗体药物缀合物，其包含特异性结合I类细胞因子受体的抗体或其抗原结合片段，其中所述抗体或其抗原结合片段与细胞毒性剂缀合。
-
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.017 seconds)
